• English
• サイトマップ
• 求人情報
• アクセス
• お問い合わせ

更新日：2019年9月10日

1. 論文
   1. 委員会承認の治療研究

      H Ishii, J Furuse, N Boku, et al.: JCOG Gastrointestinal Oncology Study Group. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40(6): 573-579, 2010.

      A Takashima, C Morizane, H Ishii, et al.: Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Jpn J Clin Oncol. 40(12): 1189-1191, 2010.

      C Morizane, T Okusaka, J Mizusawa, et al.: Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 104(9): 1211-1216, 2013.

      J Mizusawa, C Morizane, T Okusaka, et al.: Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 46(4): 385-388, 2016.

      K Nakachi, M Konishi, M Ikeda, et al.: A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 48(4): 392-395, 2018.

      J Mizusawa, A Fukutomi, H Katayama, et al.: Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Pancreatology. 18(7):841-845, 2018.

      H Kitahara, Y Honma, M Ueno, et al.: Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol. 2018 Dec 24. doi: 10.1093/jjco/hyy188. [Epub ahead of print]

   2. グループ代表者管理の治療研究

      K Nakachi, J Furuse, T Kinoshita, et al.: A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 66(3): 527-534, 2010.

      H Ueno, T Okusaka, J Furuse, et al.: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol. 41(8): 953-958, 2011.

      M Ikeda, T Ioka, Y Ito, et al.: A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 85(1): 163-169, 2013.

      M Ikeda, T Okusaka, J Furuse, et al.: A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 72(2): 463-470, 2013.

      E Suzuki, M Ikeda, T Okusaka, et al.: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 71(5): 1141-1146, 2013.

      T Yamaguchi, N Machida, C Morizane, et al.: Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105(9): 1176–1181, 2014.

      A Hagihara, M Ikeda, H Ueno, et al.: A phase I study of sorafenib combined with transcatheter arterial infusion of cisplatin for advanced hepatocellular carcinoma. Cancer Sci. 105(3): 354-358, 2014.

      M Ikeda, S Shimizu, T Sato, et al.: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol. 27(11): 2090-2096, 2016.

      M Ikeda, S Shimizu, T Sato, et al.: Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. Ann Oncol. 28(4): 903-904, 2017.

      S Hijioka, W Hosoda, K Matsuo, et al.: Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res. 23(16): 4625-4632, 2017.

      M Ikeda, T Okusaka, Y Sato, et al.: A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. Jpn J Clin Oncol. 47(6): 512-519, 2017.

      E Suzuki, S Kaneko, T Okusaka, et al.: A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. Jpn J Clin Oncol. 48(4): 317-321, 2018.

      M Ozaka, H Ishii, T Sato, et al.: A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 81(6): 1017-1023, 2018.

      S Kobayashi, T Terashima, S Shiba, et al.: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer science. 109(8): 2549-2557, 2018.

      K Nakachi, M Konishi, M Ikeda, et al.: Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol. 23(5): 894-899, 2018.

   3. 附随研究等

      なし

   4. 総説・解説

      古瀬純司: 医学と医療の最前線「膵癌化学療法の最前線」. 日本内科学会雑誌． 99: 842-848, 2010.

      M Konishi: Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. J Hepatobiliary Pancreat Sci. 19(4): 301-305, 2012.

      J Furuse, A Kasuga, A Takasu, et al.: Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci. 19(4): 337-341, 2012.

      J Furuse, H Ishii, T Okusaka: The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): history and future direction. Jpn J Clin Oncol. 43(1): 2-7, 2013.

      M Ikeda, S Mitsunaga, S Shimizu, et al.: Current status of hepatocellular carcinoma in Japan. Chin Clin Oncol. 2(4):40, 2013.

      池田公史、光永修一、清水怜、他： 分子標的治療薬　日本内科学会雑誌　103（1）：93-101, 2014.

      M Ikeda, H Okuyama, H Takahashi, et al.: Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. J Hepatobiliary Pancreat Sci. 22(8): 623-627, 2015.

      M Ikeda, S Mitsunaga, I Ohno, et al.: Systemic chemotherapy for advanced hepatocellular carcinoma: Past, Present and Future. Diseases. 3:360-381, 2015.

      M Ikeda, C Morizane, M Ueno, et al.: Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 48(2): 103-114, 2018.

      C Morizane, M Ueno, M Ikeda, et al.: New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol.1:48(8): 703-711, 2018.

2. 主な学会発表
   1. 委員会承認の治療研究

      石井浩、他: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. 第8回日本臨床腫瘍学科器学術集会. 2010年3月.

      C Morizane, et al.: Randomized phase II study of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805) (abstract 255). Gastrointestinal Cancers Symposium. Jan 2012.

      M Ueno, et al.: Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). (Abstract 4031). 2012 ASCO Annual Meeting. Jun 2012.

      C Morizane, et al.: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG 1113). (Abstract TPS4149). 2014 ASCO Annual Meeting. May 2014.

      C Morizane, et al: Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). (Abstract TPS4143). 2015 ASCO Annual Meeting. May 2015.

      A Fukutomi, et al.: Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106). Poster general session. (Abstract 4116). 2015 ASCO Annual Meeting. Jun 2015.

      T Ioka, et al.: Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106. (Abstract 621PD). ESMO 2016 Congress. Oct 2016.

      M Ikeda, et al.: A randomized phase III trial comparing adjuvant chemotherapy with S-1 vs. surgery alone in patients with resectable biliary tract cancer (JCOG1202: ASCOT). (Abstract TPS4144). 2017 ASCO Annual Meeting. Jun 2017.

      A Fukutomi, et al.: Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407). (Abstract #769TiP). ESMO 2017 Congress. Sep 2017.

      C Morizane, et al.: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). (Abstract 205). 2018 Gastrointestinal Cancers Symposium. Jan 2018.

      Y Honma, et al.: Randomized phase III study of observation versus adjuvant capecitabine and oxaliplatin in curatively resected small bowel adenocarcinoma: A Japan Clinical Oncology Group study (JCOG1502C). (Abstract TPS539). Poster Session. 2018 Gastrointestinal Cancers Symposium. Jan 2018.

      M Ueno, et al.: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). (Abstract 4014). ASCO 2018 annual meeting. Jun 2018.

      池田公史、他：進行胆道癌を対象としたゲムシタビン+シスプラチン併用療法とゲムシタビン+S-1併用療法の第III相比較試験 (JCOG1113, FUGA-BT). 第54回日本胆道学会学術集会. 2018年9月.

   2. グループ代表者管理の治療研究

      M Konishi, K Nakachi: Feasibility Study of S-1 in Resected Biliary Tract Cancer. (abstract P205). Asia Pacific HPBA Congress 2011. Sep 2011.

      小西大、仲地耕平: 胆道癌根治切除例に対するS-１による補助化学療法の安全性確認試験. 第47回日本胆道学会学術集会. 2011年9月.

      T Yamaguchi, et al.: Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. (abstract 274). Gastrointestinal Cancers Symposium. Jan 2012.

      N Machida, et al.: Multicenter retrospective analysis of systemic chemotherapy for advanced poorly differentiated neuroendocrine carcinoma of the digestive system. (abstract 4046). 2012 ASCO Annual Meeting. Jun 2012.

      仲地耕平、他: 進行肝内胆管癌に対するシスプラチン肝動注化学療法の多施設共同第II相試験. 第10回日本臨床腫瘍学会学術集会. 2012年7月.

      春日章良、他: 消化器原発低分化型神経内分泌癌に対する全身化学療法の多施設共同観察研究. 2012年7月.

      小西　大、他: 胆道癌根治切除例に対するS-1による術後補助化学療法の多施設共同臨床試験. 第48回日本胆道学会学術集会. 2102年9月.

      T Yamaguchi, et al.: Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of digestive System. 11th Annual conference of the European Neuroendocrine Tumor Society. Mar 2013.

      清水怜、他: 進行肝細胞癌を対象としたソラフェニブとシスプラチン肝動注の併用療法. 第50回日本肝癌研究会. 2014年6月.

      M Ikeda, et al.: Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phaseⅡtrial. (Abstract 4076). 2015 ASCO Annual Meeting. May 2015.

      M Morimoto, et al.: A Randomized Phase 2 Trial of Sorafenib Plus Intra-Arterial Cisplatin versus Sorafenib Alone for Advanced Hepatocellular Carcinoma. (Abstract O-022). 29th ILCA Annual Conference. Sep 2015.

      H Takahashi, et al.: Multicenter retrospective analysis of pancreatic acinar cell carcinoma: Overall survival and potential benefit of platinum- or irinotecan-containing chemotherapy. (Abstract 2313). 18thECCO-40thESMO European Cancer Congress. Sep 2015.

      小島康志、他：進行肝細胞癌に対するソラフェニブとシスプラチン肝動注療法のランダム化第Ⅱ相試験. 第53回日本癌治療学会学術集会. 2015年10月.

      M Ueno, et al.: Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. (Abstract 4111). 2016 ASCO Annual Meeting. Jun 2016.

      M Ozaka, et al.: Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC). JPS Symposium 8. Advances for Chemotherapy in Pancreatic Cancer. 47th Annual meeting of the Japan Pancreas Society, 20th IAP, 6th AOPA. Aug 2016.

      寺島健志，他：Multicenter retrospective study of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. 第15回日本臨床腫瘍学会学術集会. 2017年7月.

      K Umemoto, et al.: FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 polymorphism: A multicenter, retrospective study. (Abstract 484). 2018 Gastrointestinal Cancers Symposium. Jan 2018.

      S Kobayashi, et al.: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. (Abstract 303). ILCA Annual Conference. Sep 2018.

      H Okuyama, et al.: A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy. (Abstract 2551). ESMO 2018 Congress. Oct 2018.

      H Takahashi, et al.: Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). (Abstract 731P). ESMO 2018 Congress. Oct 2018.

      C Morizane, et al.: A Phase II Study of Everolimus in Patients with Unresectable Pancreatic Neuroendocrine Carcinoma. 16th Annual ENETS Conference. Mar 2019.

      Nara S, et al.: The assessment of preoperative diagnostic accuracy of multidetector-row computed tomography (MDCT) for resectable biliary tract cancer- multi-institutional validity study in Japan. (Abstract 141). Digestive Disease Week. May 2019.

      H Tsumura, et al.: Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. JSMO 2019 Congress. Jul 2019.

      C Morizane, et al.: First-line chemotherapy for advanced biliary tract cancer, Japanese phase III studies. JSMO 2019 Congress. Jul 2019.

      M Ikeda, et al.: Everolimus for advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based chemotherapy. JSMO 2019 Congress. Jul 2019.

   3. 附随研究等

      N Mizuno, et al.: Effect of inflammatory and nutritional (IN) status on induction chemotherapy (CT) followed by chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC): an exploratory subgroup analysis of JCOG1106. (Abstract 4123). 2017 ASCO Annual Meeting. Jun 2017.

      S Kobayashi, et al.: Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer: an integrated exploratory analysis of JCOG1106 and LAPC-S1RT. (Abstract 301). 2019 Gastrointestinal cancers symposium. Jan 2019.

      I Yamada, et al.: The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory analysis of JCOG1113. (Abstract 349). 2019 Gastrointestinal cancers symposium. Jan 2019.

      M Ueno, et al.: The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113. (Abstract 368). Gastrointestinal cancers symposium. Jan 2019.

   4. 総説・解説

      森実千種、他：希少がんの臨床研究と研究体制づくり：消化器NEC. 第16回日本臨床腫瘍学会. 2018年7月.